Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms
- 30 April 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 17 (5), 661-668
- https://doi.org/10.1517/13543784.17.5.661
Abstract
Background: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent. Objective: To review what is known about polymyxin B and to identify missing information or gaps for future investigations. Methods: Pertinent information was reviewed from published literature in English. Results/conclusion: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.Keywords
This publication has 39 references indexed in Scilit:
- Polymyxin B: similarities to and differences from colistin (polymyxin E)Expert Review of Anti-infective Therapy, 2007
- Polymyxin B for the treatment of multidrug-resistant pathogens: a critical reviewJournal of Antimicrobial Chemotherapy, 2007
- Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria.Cleveland Clinic Journal of Medicine, 2007
- WHEN TO INCLUDE POLYMYXINS IN THE EMPIRICAL ANTIBIOTIC REGIMEN IN CRITICALLY ILL PATIENTS WITH FEVER? A DECISION ANALYSIS APPROACHShock, 2007
- Polymyxin B and Doxycycline Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care UnitAnnals of Pharmacotherapy, 2006
- The Use of Intravenous and Aerosolized Polymyxins for the Treatment of Infections in Critically Ill Patients: A Review of the Recent LiteratureClinical Medicine & Research, 2006
- Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004)Clinical Microbiology & Infection, 2006
- Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin BEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patientsJournal of Antimicrobial Chemotherapy, 2004
- Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control GuidelinesJournal of Clinical Microbiology, 2001